Pharmatica

In this special Scientific Council Spotlight episode of The Discovery Loop podcast, host Shubhangi Dua, Journalist, Podcast Producer and Podcast Host at Pharmatica.io, sits down with Deepankar Nayak, the CEO of Deep Longevity. Nayak also serves on Pharmatica’s Scientific Council.

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."

In the recent episode of The Clinical Compass podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, is joined by Dr Amber Hill, Founder and CEO of Research Grid. They talk about how pharmaceutical companies and their leaders should approach the use of AI in clinical trials.

In the recent episode of The Discovery Loop podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io, sat down with Diana Andrade, Founder & Managing Director at RD Privacy and Data Protection Officer (DPO) for Biopharma and Life Sciences. They talk about the current state of data protection regulations and how enterprises can innovate responsibly.

In the recent episode of The Chain Reaction podcast, Nour AlSaleh, Founder and CEO of Veragence Pharma Consultancy, sat down with host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io and EM360Tech. AlSaleh shares her expertise on maintaining data integrity in this new era of AI and changing policies.

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

In the recent episode of the Digital Pulse podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, sat down with Lara Masad, an AI and Data Innovation independent consultant, to clarify the key distinctions in AI and machine learning models. Furthermore, Masad explains how pharmaceutical companies benefit from using AI models.

Trisha Pillay speaks with Judit Mora, CEO of Nuumad, on Digital Pulse discussing pharmacy innovation, market access barriers, and new models for faster patient access to healthcare.

Trisha Pillay speaks with Dineshree Naiker, co-founder of Umsebe Healthcare, on Chain Reaction discussing regulatory leadership, pharmaceutical supply chains, and improving patient access to medicines.

Exclusive Pharmatica Content

Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.

Nicole Dale

Foundational AI In Cell and Gene Therapy Development Success

Pharmatica image representing AI in cell and gene therapy development success through improving drug discovery, viral vector engineering, manufacturing, and predictive quality control.

Discover why AI in cell and gene therapy is necessary for successful development by improving drug discovery, viral vector engineering, manufacturing, and quality control.

Nicole Dale

Why CMC Strategy Defines Cell and Gene Therapy Success

Pharmatica image of a modern cell and gene therapy manufacturing facility supporting advanced CMC strategy through GMP production, digital process monitoring, pharmaceutical quality systems, and bioprocess innovation.

Cell and gene therapy CMC strategies, quality systems, and manufacturing innovation are critical to advanced therapy development and determine scalability.

Nicole Dale

One Pivotal Trial for FDA Approval? Success Depends on Trial Design

Pharmatica image of a modern pharmaceutical regulatory affairs workspace representing documentation, compliance, and submission processes essential for FDA drug approval. The scene shows three binders labeled “Regulatory Affairs,” “Submissions,” and “Compliance” on a clean office desk with documents and a pen in the foreground, while a blurred meeting of professionals is visible through a glass wall in the background. The composition conveys administrative precision and regulatory science underpinning.

One pivotal trial for FDA approval could accelerate drug development, reshape clinical trial strategy, and change the pharmaceutical regulatory landscape.

Nicole Dale

Europe’s Life Sciences Strategy. A New Era of Innovation?

Pharmatica picture of European pharmaceutical innovation showing biotechnology research, advanced manufacturing, artificial intelligence, and regulatory collaboration supporting the European Life Sciences Strategy.

The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.

Nicole Dale

One Global CMC Dossier? Digital Regulatory Submissions

Pharmatica photo‑realistic representation of CMC regulatory submissions showing global data networks, secure digital dossier exchange, and pharmaceutical manufacturing integration — document binders, connected globe, red padlock cybersecurity icon, and industrial equipment with red‑capped vials illustrate digital CMC submissions, regulatory reliance, and manufacturing quality.

Discover how digital CMC regulatory submissions, cloud collaboration, and AI accelerate the modernisation of manufacturing approvals and global pharma operations.

Nicole Dale

FDA PreCheck Pilot Program to Build Manufacturing Readiness

Pharmatica image of regulatory inspectors reviewing digital drug manufacturing systems in a pharmaceutical production facility, illustrating the FDA PreCheck Pilot Program, manufacturing readiness, U.S. domestic drug manufacturing, and advanced pharmaceutical manufacturing.

The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.

Nicole Dale

FDA Master Protocol Guidance for Smarter Clinical Trials

Clinical research laboratory featuring a Master Protocol document, laboratory samples, and digital analytics, representing clinical trial efficiency for precision medicine research under the FDA Master Protocol guidance.

Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.

Nicole Dale

Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?

Operation TrialBlazer aims to reshape U.S. clinical trials by combining FDA regulatory innovation, digital technologies, and modern trial strategies to reclaim global leadership in pharmaceutical development.

Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.

Nicole Dale

FDA Registration for Drug Manufacturing Enters a New Era

Modern pharmaceutical manufacturing facility with stainless steel equipment, automated vial conveyor, and red digital data wave overlay symbolising FDA regulatory oversight and digital quality systems.

The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.

Nicole Dale

AAV Vector Manufacturing: Solving Gene Therapy's Bottleneck

Scientist’s gloved hands handling a vial and pipette in a bright laboratory with a glowing DNA helix and AAV capsid, representing advanced AAV vector manufacturing and gene therapy process development.

Discover how innovations in AAV vector manufacturing are improving scalability, quality, and commercial readiness for next-generation gene therapies.

Nicole Dale

Digital Measures in Clinical Trials: FDA vs EMA Pathways

Clinician reviewing digital measures in clinical trials on a tablet, illustrating regulatory acceptance of digital health technologies, digital biomarkers, and FDA and EMA qualification pathways for modern clinical research.

Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.

Nicole Dale

FDA Draft Guidance on Gene Editing Safety (2026)

DNA double helix illustrating the FDA gene editing draft guidance 2026, highlighting next-generation sequencing (NGS) safety assessment, off-target editing analysis, genomic integrity testing, and regulatory requirements for cell and gene therapy development.

The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.

Content type

Topic

Articles, expert interviews, and insights from life sciences leaders

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

Foundational AI In Cell and Gene Therapy Development Success

Why CMC Strategy Defines Cell and Gene Therapy Success

One Pivotal Trial for FDA Approval? Success Depends on Trial Design

Europe’s Life Sciences Strategy. A New Era of Innovation?

One Global CMC Dossier? Digital Regulatory Submissions

FDA PreCheck Pilot Program to Build Manufacturing Readiness

FDA Master Protocol Guidance for Smarter Clinical Trials

Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?

FDA Registration for Drug Manufacturing Enters a New Era

AAV Vector Manufacturing: Solving Gene Therapy's Bottleneck

Digital Measures in Clinical Trials: FDA vs EMA Pathways

FDA Draft Guidance on Gene Editing Safety (2026)